🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
7.44
+0.20 (2.76%)
Nov 18, 2026, 10:03 AM EST - Market open
← View all transcripts

Stifel 2026 Healthcare Conference 2026

Nov 11, 2026

Summary

RGX-314 wet AMD pivotal results are expected before year-end, with treatment-burden reduction among key secondary goals. Commercial preparation includes a trained surgeon network, while the NAAVIGATE DR study is ramping and RGX-202’s accelerated-approval case centers on functional and safety data.

Annabel Samimy
Managing Director, Stifel

All right. Good morning, everyone, and thank you for coming to the Regenxbio session. Regenxbio, as you know, is a very solid, vertically integrated gene therapy company focused on muscular, rare muscular diseases, as well as large retinal diseases. So, a two-track approach. With us today is Curran Simpson, CEO, Steve Pakola, Chief Medical Officer, and Ram Palanki, who is Chief Commercial Officer, as you are soon transitioning to commercial, so you are going to be a very important person up here, Ram. First, why don't we get a good overview of where you stand today?

Level the playing field for everyone, and then we can launch into questions.

Curran Simpson
CEO, Regenxbio

Great. When I was riding up on Amtrak, I was thinking about the first RGX-314 experiments I saw coming out of Jim Wilson's lab in Pennsylvania, and here we are 10-plus years later.

Just weeks away from our top-line data. So it's an exciting time. These are the largest gene therapy studies ever conducted, and we are super excited to work with AbbVie on this program. They've been with us for about three and a half years to sort of unveil the results. I think we are really confident in the data. We've spent a lot of time, Steve can attest, in phase one, two development, finding the ideal doses for a pivotal program. We did a really comprehensive pharmacodynamic study to look at our commercial process in a clinical setting, and I think that's all set the table for these two large studies to read out, and in a great way, on top of each other. So we will have data in a joint release soon before the end of this year with AbbVie announcing the top-line results.

Yeah.

Annabel Samimy
Managing Director, Stifel

Very excited.

Curran Simpson
CEO, Regenxbio

Confident and excited, and all the things that go into drug development. It has been a great ride, and we are looking forward to seeing how that data looks in a few weeks.

Annabel Samimy
Managing Director, Stifel

Great. Why don't we talk about this program a little? You have mentioned multiple times it is the largest gene therapy trial. They are the largest gene therapy trials, because there are two of them.—

Curran Simpson
CEO, Regenxbio

Yeah.

Annabel Samimy
Managing Director, Stifel

—ever conducted. Maybe you can just lay that out for us, explain to us, or describe exactly how expansive they are, what you are looking for with the primary endpoints, what are the benchmarks that people should be looking at?

Curran Simpson
CEO, Regenxbio

Great. Yeah, maybe I will let Steve walk through the design.

Steve Pakola
CMO, Regenxbio

Sure. Thanks, Annabel. Yes, this is the largest gene therapy program ever conducted, but it is also important to point out that it is also the most comprehensive program, and that really goes for the overall program, including the initial clinical studies, including the pharmacodynamic study that Curran mentioned. I think another key point is these trials had the benefit of multiple prior studies from which to make dose selection, to make decisions on all the different inclusion/exclusion criteria, retreatment criteria, where we had an opportunity to have very good data from phase II and to really replicate all these different variables so that we do not have that risk of not replicating what we saw in our prior studies. So, what do we want to show?

We, of course, want to show good visual acuity results, and that is the primary endpoint, but we also, of course, need to show that you can achieve that even with a dramatic reduction in treatment burden, and also sustain disease activity. So that speaks to the endpoints that we care about. The basic design is previously treated wet AMD patients with a history up to four years of treatment. In terms of comprehensive, the key thing here is because of what we had seen previously and really the route of administration that we chose, subretinal, we are able to get to doses without any immune-mediated safety issues where we believe that we can treat tougher-to-treat patients.

Our inclusion criteria allow patients who do have a higher treatment burden in a way that other programs don't have that flexibility to include. That's a key aspect because that's what clinicians want to treat.

We hear that over and over again. The biggest unmet need for them and their patients is these tougher-to-treat patients, and that's ideally who they want to treat with a one-time gene therapy. So those patients come in the trial. In these two trials, it's over 1,300 patients. The basic design is really tried and true, so there's no regulatory risk to the approach if we can meet the primary endpoint. Its primary endpoint is non-inferiority—

—to on-label anti-VEGF. In one treatment arm, it's monthly Lucentis, and in the other, it's loading doses plus every other month of aflibercept. We also have the benefit to increase probability of success that we were able to go with two arms of sura-vec. We have a low dose and a high dose. Primary endpoint is non-inferiority on change from baseline best corrected visual acuity at 54 weeks, highly no regulatory risk there. We have the key secondary endpoints of reduction in injection burden, where again, we've seen very good response in all our prior studies. Also the goal to have a reasonable proportion of those patients have need for no injections over the year. Another key one is you want to see disease stability anatomically. We also want to see stability or improvement on retinal thickness measured by OCT.

Lot of work.

Annabel Samimy
Managing Director, Stifel

Yeah.

Steve Pakola
CMO, Regenxbio

from us and AbbVie, but almost there.

Annabel Samimy
Managing Director, Stifel

Yeah. A few more questions around that. So you have two doses. You mentioned that you're testing a lot of patients who are high burden. Are you planning on moving forward with two doses? Are you having two doses so you can capture a broader range of patients, both with high burden, maybe with low burden? And if you're capturing those patients, what does that say to the potential variability within the trial of that patient group?

Steve Pakola
CMO, Regenxbio

Yeah, so.

Annabel Samimy
Managing Director, Stifel

That's three questions in one.

Steve Pakola
CMO, Regenxbio

Yeah.

Annabel Samimy
Managing Director, Stifel

Sorry.

Steve Pakola
CMO, Regenxbio

I'll go with the last, which means I may forget the earlier part.

Annabel Samimy
Managing Director, Stifel

I might have already forgotten my question.

Steve Pakola
CMO, Regenxbio

Well, if any of us remember, we'll say it. We have to see what the results are, of course.

Annabel Samimy
Managing Director, Stifel

Yeah.

Steve Pakola
CMO, Regenxbio

I think there's always some aspect of very good results in phase I, II. We saw very good results with both these doses and doses similar to these. And we saw good efficacy. I think in that setting, if you want to go big and you want to increase your probability of success, you never know until you do the big studies with bigger N how the safety and efficacy will pan out. So, like any program that has two arms, when you go into pivotal, it's pretty common in retina, actually, to have those two arms of your drug in the pivotal. And if both are effective, and the high dose is more effective, great, you go with that. If they're the same, you might go with the lower.

But I think our view is either dose, we saw a really good response even in that tougher-to-treat patient population. And we'll get to evaluate that in subgroup analysis, high dose and low dose, how well were you able to treat those tougher-to-treat patients.

Annabel Samimy
Managing Director, Stifel

Does it impact the powering at all for each of the different arms? Or is each arm well-powered for-

Steve Pakola
CMO, Regenxbio

Yeah, so we took that into account and aligned with the FDA on the typical alpha corrections-

if you're looking at both. So that's incorporated into the sample size and achieving 90% power. So, that's the other de-risking, of course.

Annabel Samimy
Managing Director, Stifel

Okay. Then, maybe you can speak to the potential variability of the patient group.

Steve Pakola
CMO, Regenxbio

You remembered it.

Annabel Samimy
Managing Director, Stifel

I did remember it.

Steve Pakola
CMO, Regenxbio

I forgot that one.

Annabel Samimy
Managing Director, Stifel

It is still early in the morning, but I am very happy about that.

Steve Pakola
CMO, Regenxbio

Yeah, so you do have that aspect of easier to treat, tougher to treat. But one, the flip side is it is all treatment experience.

So we are not mixing naive plus treatment experience, where we think that actually would be the—

Annabel Samimy
Managing Director, Stifel

Okay.

Steve Pakola
CMO, Regenxbio

—greater level of variability. And again, the variability that you would anticipate is also taken into account—

—to the sample size. That is part of having these largest trials, on top of AbbVie's desire to—

—to really have good power even on secondary endpoints for global value proposition—

Annabel Samimy
Managing Director, Stifel

Yeah.

Steve Pakola
CMO, Regenxbio

—considerations.

Annabel Samimy
Managing Director, Stifel

I guess, a point to make is treatment experience, but also VEGF responsive.

Steve Pakola
CMO, Regenxbio

Yes, and that is another key aspect where we have a design where we are not indirectly or trying to exclude these tougher-to-treat patients that are the most clinically relevant for the clinicians in that patients have to be anti-VEGF treatment responsive. So there is a screening anti-VEGF. And instead of looking one month after that screening injection, we look one week after, where if a patient is treatment responsive, you are going to see it there. If you look at one month, the really tougher-to-treat patients are going to get screened out because even though they had an initial response, they have such a VEGF drive that they start to lose at least part of that response by the four-week time period. So, because of our subretinal delivery and our product, we are confident to go after that patient population. So we have no desire to exclude that group.

Our pivotal trials are going to do what you want to do if we hit, of course, from a regulatory standpoint. But ultimately, from a commercial standpoint, the clinicians need to know what would you see in-

Annabel Samimy
Managing Director, Stifel

In treatment-

Steve Pakola
CMO, Regenxbio

the patients that I care about.

Annabel Samimy
Managing Director, Stifel

In a very high treatment burden patient.

Steve Pakola
CMO, Regenxbio

Yes.

Annabel Samimy
Managing Director, Stifel

Okay. Can you remind us the secondary endpoints that you are looking at and what you want to see there?

Steve Pakola
CMO, Regenxbio

Sure. Treatment burden.

We want to see a meaningful reduction. For us in AbbVie, that target product profile is over 50%—

—reduction. We have confidence on that from our prior trials where we have always hit that. We also want to see a sizable proportion of patients that do not need any injection.

Annabel Samimy
Managing Director, Stifel

Okay.

Steve Pakola
CMO, Regenxbio

You can anticipate, because that is such an important aspect for the program and for the clinicians, that will be one of the points that would come out in any top line release that we and AbbVie would jointly—

Annabel Samimy
Managing Director, Stifel

Got it.

Steve Pakola
CMO, Regenxbio

—do.

Annabel Samimy
Managing Director, Stifel

Got it. I guess maybe we can speak to, I guess, the biggest concern for us. I mean, there seems to be a big disconnect between the value that investors see in this program and the value that the KOLs see in gene therapy, just gene therapy in general, and then gene therapy, this specific program. What is not well understood yet? Because, I mean, you had your investor day on 314 specifically, and the KOLs seemed to be very excited about the opportunity of having a gene therapy. Where do you think the biggest disconnect lies? Is it in subretinal administration? Is it in the fact that there are plenty of anti-VEGF treatments that work? Is it a safety question? What are your thoughts around that, and what are we not understanding?

Curran Simpson
CEO, Regenxbio

Yeah, I think we will let Ram maybe speak to that, but I think the question from many years ago has always been the subretinal route of administration, and are retinal specialists willing to move patients into that type of a scenario? I think what we are hearing is that there is a lot of enthusiasm for that. Maybe you can speak to what did we learn on October 20th when we did our investor day?

Ram Palanki
CCO, Regenxbio

Yeah, I think you and I have spoken about this, Annabel, a few times. I think the fundamentals there, retina went from a surgical specialty to a medical specialty. I think what people forget is because of the volume of medical procedures that are done, that they are still fundamentally surgeons. You take a poll, ASRS does this every year, 90% of them are surgeons, and they do 500,000 procedures in the country today. I think the fundamentals are people forget that they do these 500,000 procedures, which the base procedure there is vitrectomy, and that is what we do, right? We say subretinal, but I think you have to think about how do you do subretinal? You do a vitrectomy because you are trying to create access to the back of the eye. Once that is done, it is a simple injection, right?

It takes about the same amount of time as like you would inject an intravitreal injection. The competency exists, the infrastructure exists, and then we look at what we have done in the clinical trial is we have established a very large footprint, right? We have trained over 300 surgeons in the country today. Those 300 surgeons actually manage almost 60%-70% of the patient volume today that has wet AMD. You start thinking about the overlaps we have with the existing infrastructure, the volume of the patients, and how many patients they have to take into the OR because they have an existing infrastructure and they have capacity already. When we go to the market, you can think about these 300 plus surgeons being ready to go, right? I think when you start thinking about gene therapy, you are shifting the conversation.

This is not like going from Lucentis to Eylea to Vabysmo. You are going to pick patients that have this high disease activity and very high treatment burden. You are not going to pick patients that have low treatment burden and low disease activity, right? When you get to the market, you have to think about how many of those patients exist, and we have done a lot of analysis to look at, if you take the claims data today and patients that are getting more frequent injections than the labeled dosing regimen, that almost represents 300,000 patients in the country. Again, 60%-70% of those reside with our 300 surgeons we have trained, right? It is an immediate adoption that we see when we go to the market with those surgeons, and then over time, it is going to expand.

You can do 70, 80 patients a day with subretinal, right? Because you have to go into the OR. I think the number of procedures you can do will be limited by the capacity itself and the patients they have to manage. But it represents, I always say, if each surgeon did even five surgeries a month, and you take about 500 surgeons in the country doing that is a significant opportunity for the asset, right? Those are the basics when you think about where you want to go and how you want to look at this. But people don't think through these things, right? They think about intravitreal, oh, it's done in the office, it's easy surgeries and SR. People are not thinking that it's an existing competency. Most people that we speak to don't even know the numbers.

They don't know that these guys wake up every week and go into the OR and do these procedures and they have access to it. I think that's the disconnect.

Annabel Samimy
Managing Director, Stifel

I think sometimes is it forgotten that it's a one and done treatment?

Ram Palanki
CCO, Regenxbio

Yes.

Annabel Samimy
Managing Director, Stifel

You have one chance to do this, and you want to do it correctly.

Ram Palanki
CCO, Regenxbio

Yeah. I think that's another part is when you're giving a one-time event, right? That patient has one chance.

They either get sura-vec or they might pick other choices as a one-time treatment, but then you have to start comparing them. What does that do to the patient? I think Steve talked about this. We have a bilateral program. We've shown that being in an immune-privileged space, the second eye doesn't get affected. We know up to 50% of patients over time develop bilateral disease. When you're making the decision, you have to keep that in context, right? Because if you pick a treatment, you want to think about the second eye—

Annabel Samimy
Managing Director, Stifel

Yeah.

Ram Palanki
CCO, Regenxbio

—really clearly. Then the net burden of treatment. Listen, I think it's really important to understand that an existing competency that has a very low burden in terms of once you do the procedure and you send the patient home, you don't have to worry about it, right? Maybe in the OR it's taking you a little bit more time, but again, it's a one-time event. If you think about intravitreal options you could potentially have with gene therapy, there's a net burden of four to six months of steroids. In real world, that's a big compliance issue.

All it takes is few patients not to take drops here and there, because then I take dry eye drops and I can't keep up with it. It's like taking two drops a day. I think the fundamentals there are the decisions you have to make based on what options you will have will be, how do you treat this patient over time, and what are the compliance issues, right? If you take bilateral, this is, let's just say IVT shows that you can do it bilaterally. Now you're talking about one year of steroids for patients once you go into the second eye. Now you're managing patients for almost eight to 12 months of steroids. All it takes is a very short period of non-compliance for something to start, and then you can't stop it.

Annabel Samimy
Managing Director, Stifel

There is an issue of whether they have glaucoma or whether they-

Ram Palanki
CCO, Regenxbio

Yes, and all the comorbid conditions.

If you have glaucoma, it is not even a starting point to put them on steroid drops.

Even if you do not have glaucoma, you have to think about four to six months of steroids—

Annabel Samimy
Managing Director, Stifel

Right.

Ram Palanki
CCO, Regenxbio

—means you are going to give glaucoma to the patients, and then you have to manage them with glaucoma drops. All these things kick in. I think the totality of that net burden, nobody understands when you are not a clinician and the patient is sitting in front of you. And then even clinicians are not thinking about it till you remind them.

Right? When you start having the conversation, they go, Yeah, these are all problems.

Annabel Samimy
Managing Director, Stifel

Right. I guess one other point of resistance, is the patient resistant to having a subretinal treatment versus an intravitreal treatment? Maybe you can talk about the patient side of it. How receptive have they been in your experience in the clinical trials? How satisfied have they been?

Ram Palanki
CCO, Regenxbio

I mean, this is a physician-driven market.

I think patients do what physicians tell them is the right thing to do.

Annabel Samimy
Managing Director, Stifel

That's fair.

Ram Palanki
CCO, Regenxbio

First, it's a pretty straightforward procedure. You don't have It's a local anesthesia.

If you think about intravitreal, you do local anesthesia. It's not like you're just going and doing it. The fundamental concepts are all the same. It's the vitrectomy part that takes about 15-20 minutes, and then you do the subretinal procedure. I think the way they have this conversation is it's under local anesthesia. We'll be speaking to you as we do the procedure. It's done, and you send them home, and then you don't have to worry about any of these, right?

In our clinical trials, our own experience is everybody that has experienced the first eye has signed up for the bilateral treatment.

I think Steve can speak to it.

Annabel Samimy
Managing Director, Stifel

Yeah, what percent signed up for bilateral?

Steve Pakola
CMO, Regenxbio

Well, one aspect is you have to meet the criteria—

Annabel Samimy
Managing Director, Stifel

Yeah.

Steve Pakola
CMO, Regenxbio

—of course. But if you have met the criteria, the response we have heard from the clinicians themselves is the patients readily sign up. They are excited to get the other eye treated. That is walking the walk and actual evidence-

of the excitement of the clinician plus the patient.

Annabel Samimy
Managing Director, Stifel

Yeah. Can you just review the infrastructure again that is required for the physician to adopt this treatment from the reimbursement perspective? Is it already kind of established for them?

Ram Palanki
CCO, Regenxbio

Yeah, so every procedure you have to think about, there is a CPT code that is what the procedure that the physician performs. I think when you go into the OR, there is a facility fee as well because there is a time and staff component that gets reimbursed. So ASCs, which are owned by either hospitals or by private physicians, they get paid on the facility time itself, right? Then the subretinal procedure, because it is a new code, the good news is, because Luxturna came to market and others came to market, they have already gone through the process of setting the precedents and getting the CPT codes in place for subretinal.

This becomes an add-on code to vitrectomy. In totality between both of those, for a 20-minute procedure, you are talking about $1,500. Then the facility, if you own it, will also get paid for that facility time. It depends if it is in a HOPD setting or an ASC setting, those payments tend to be different, but they are thousands of dollars. Once you go through the process, you have to think about, okay, I have to buy the drug and bill for it. Those pathways already exist, and people have been doing very successfully. An ASC or HOPD will get paid that 6% over WAC.

In some ways, if you look at the data for Encelto and Luxturna, they have gotten very comfortable with it. Now they also know that there is an economic component as you do this buy and bill process. The fundamentals are it is a very sustainable, and the net recovery concept exists already. We do not have to teach them anything. They are very comfortable with all of this.

Annabel Samimy
Managing Director, Stifel

Okay, got it. I know we are quickly running out of time. I want to touch on DR a little bit. Obviously, this is a new area with a new mode of administration through suprachoroidal. Why suprachoroidal for this one versus subretinal?

Steve Pakola
CMO, Regenxbio

Yeah, right from the beginning when we evaluated this, we always wanted to add on and have an in-office—

—procedure, particularly for different indications like DR that I will explain in a minute. The key thing for us was we got to preserve the great things about subretinal when we pick a delivery method. For us, SCS does that—

—because it keeps it localized and basically close to the target tissue, right at the target tissue, and prevents off-target tissue issues. For us, the biggest opportunity was diabetic retinopathy.

I mean, this is a space where if you can get to patients before they develop the vision-threatening complications of PDR and DME, that is what is missing right now. These patients are a ticking time bomb once they develop moderately severe to severe NPDR. Now, why suprachoroidal instead of subretinal? They are at this high risk before they develop these blinding complications, but they are asymptomatic or relatively asymptomatic. So, it just makes it a much tougher lift to go through a more time-consuming procedure and an albeit simple surgical procedure. This is totally untapped, this space, because patients who are in that state, asymptomatic but at high risk, they do not want to sign up, and their doctors do not want to sign them up for repeated injections.

Even if you can increase the durability or you have agents where you can increase the interval of injections, anything that is indefinite, basically for the rest of the patient's life, that is a non-starter. We see that because even on-label repeat anti-VEGF injection drugs are just simply not being used here. We hear over and over from the clinical community, Wow, if you can have an in-office one-time treatment, we could really go after this population. We have three-year data from our phase II study where we have seen, in fact, we can improve diabetic retinopathy severity, and we can actually greatly decrease the risk or the actual development of the VTCs.

Annabel Samimy
Managing Director, Stifel

And those numbers improved over time.

Steve Pakola
CMO, Regenxbio

That is what is really striking. This is three years after a single injection.

We are seeing better results at three years than we saw at one and two years. It is based on those results that we and AbbVie really accelerated this program to start a phase II-B/III study, the NAAVIGATE study, that we started earlier this year, and we are ramping up there.

Annabel Samimy
Managing Director, Stifel

Great. I do want to leave some time for 202 and Duchenne's disease. This is clearly approaching BLA completion in the first quarter. The data have been pretty comprehensive, and I think there are still question marks in people's minds with whether this can be an accelerated approval. There is a lot of noise in gene therapy right now, obviously, with the issues with Zolgensma. Maybe you can speak to that and why you still feel comfortable with an accelerated approval, and just in general with the sort of the cloud over this area right now.

Curran Simpson
CEO, Regenxbio

Yeah. I was actually at a meeting at FDA earlier this week and posed the question of, when does the circular argument about RCT versus single-arm study end in rare disease? There is a new framework being developed by FDA in collaboration with industry on rare disease development. Karim Mikhail was really clear to say that there are a number of products being approved based on single-arm studies as we speak. You can see them every month coming through. I think the question of, is data from a single-arm study acceptable for review and potential approval using the AA pathway, is being answered in the field as we speak. And the strength of it is what is really needed in a single-arm study, we have two things that I think no other study has had.

Magnitude of effect that people believe is well beyond what would be expected from natural history, correlation of the biomarker with functional benefit, which was not seen in Elevidys. It is actually in the AdCom minutes and in the label. We have a strong correlation between the level of microdystrophin we have shown and functional benefit on NSAA at 12 months, and we have a magnitude of effect NSAA results versus baseline and external control matching that is well beyond what you would say is a minimally clinically important difference. So, the basis, I think, of our submission is based on a dataset that everyone that has looked at it, even the biggest skeptics that were around when Elevidys was being reviewed, look at our data and say, This is awesome. This is really what the field has been looking for.

And we cannot wait to present that to FDA in a pre-BLA setting.

Annabel Samimy
Managing Director, Stifel

That is great. So, I guess you have the confirmatory study going on right now. You are going to have a safety database from those patients. But you also started a randomized controlled trial for a European file or a global filing.

I guess one of your other competitors has a randomized controlled trial going on right now. Are there any possibilities where the FDA waits for your randomized controlled trial or turns around and says, Well, this guy has a randomized controlled trial. Maybe you should have one too. What are you sensing from FDA in terms of what they are going to require of you?

Curran Simpson
CEO, Regenxbio

I think we sense that's more likely to be a post-approval commitment off an accelerated approval. For the reason that if we map out timelines for anyone's study, whether it's ours or others in the field, those RCT studies won't read out probably until 2029, maybe 2030. I don't see the Duchenne community being comfortable waiting until then for options that they can choose. I think the partnership that we have with the Duchenne community, the urgency, the unmet need, the treatment level for Elevidys right now is below the incidence level of the disease. The prevalent population is growing every day right now, and that speaks to the unmet need. I think that'll be something FDA will have to weigh versus waiting three more years to read out another study.

I think the important driver for us, one of them, in the AA approach is safety. You don't need 1,000 patients to demonstrate what is probably a tenfold reduction in liver injury. We've seen that already in our data. I think that this will be a really compelling package to review.

Annabel Samimy
Managing Director, Stifel

Okay. We're over time, but one last bit. Cash, potential milestones coming. Maybe you can just tell us where you are there.

Curran Simpson
CEO, Regenxbio

Yeah. We have milestones in place as the filing for the 314 program proceeds off top-line data. We have milestones in the future for sales, first patient dosed commercially. We have cash beyond our PDUFA date for the Duchenne program. So, we're in good shape to get to these key milestones and continue to move forward.

Annabel Samimy
Managing Director, Stifel

Great. We're waiting with bated breath about wet AMD.

Curran Simpson
CEO, Regenxbio

We're going to put Steve in the basement now for [crosstalk]

Annabel Samimy
Managing Director, Stifel

Yeah. You're not allowed to come out until it's out. All right. Thank you very much.